Skip to content

A Prospective Randomized Controlled Clinical Trial of Different Surgical Intervention of TG13 Grade II Acute Cholecystitis.

A Prospective Randomized Controlled Clinical Trial of Different Surgical Intervention of TG13 Grade II Acute Cholecystitis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17013103
Enrollment
Unknown
Registered
2017-10-25
Start date
2018-07-01
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Cholecystitis

Interventions

A:Emergency laparoscopic cholecystectomy
B:Emergency PTGBD+Elective LC

Sponsors

The Seventh Affiliated Hospital, Sun Yat-sen university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of TG13 grade II for acute cholecystitis; 2. Aged between 20 to 69 years old; 3. No gender limitation; 4. No serious internal medicine disease.;Inclusion criteria: 1. Patients who meet the diagnostic criteria of TG13 grade II for acute cholecystitis; 2. Aged between 20 to 69 years old; 3. No gender limitation; 4. No serious internal medicine disease.;Inclusion criteria: 1. Patients who meet the diagnostic criteria of TG13 grade II for acute cholecystitis; 2. Aged between 20 to 69 years old; 3. No gender limitation; 4. No serious internal medicine disease.;Inclusion criteria: 1. Patients who meet the diagnostic criteria of TG13 grade II for acute cholecystitis; 2. Aged between 20 to 69 years old; 3. No gender limitation; 4. No serious internal medicine disease.;Inclusion criteria: 1. Patients who meet the diagnostic criteria of TG13 grade II for acute cholecystitis; 2. Aged between 20 to 69 years old; 3. No gender limitation; 4. No serious internal medicine disease.

Exclusion criteria

Exclusion criteria: 1. combined significantly high risk of anesthesia (ASA IV or above); 2. Combination of serious internal medicine disease and with poor drug control; 3. Have a history of upper abdominal surgery; 4. Do not agree to participate in the study.;Exclusion criteria: 1. combined significantly high risk of anesthesia (ASA IV or above); 2. Combination of serious internal medicine disease and with poor drug control; 3. Have a history of upper abdominal surgery; 4. Do not agree to participate in the study.;Exclusion criteria: 1. combined significantly high risk of anesthesia (ASA IV or above); 2. Combination of serious internal medicine disease and with poor drug control; 3. Have a history of upper abdominal surgery; 4. Do not agree to participate in the study.;Exclusion criteria: 1. combined significantly high risk of anesthesia (ASA IV or above); 2. Combination of serious internal medicine disease and with poor drug control; 3. Have a history of upper abdominal surgery; 4. Do not agree to participate in the study.;Exclusion criteria: 1. combined significantly high risk of anesthesia (ASA IV or above); 2. Combination of serious internal medicine disease and with poor drug control; 3. Have a history of upper abdominal surgery; 4. Do not agree to participate in the study.

Design outcomes

Primary

MeasureTime frame
operation time;hospital stays;Total hospitalization expenses;

Secondary

MeasureTime frame
Intraoperative blood loss;conversion rate to the open procedure;

Countries

China

Contacts

Public ContactChen Yang;Chen Yang;Chen Yang;Chen Yang;Chen Yang ;;;;

The Seventh Affiliated Hospital, Sun Yat-sen university;The Seventh Affiliated Hospital, Sun Yat-sen university;The Seventh Affiliated Hospital, Sun Yat-sen university;The Seventh Affiliated Hospital, Sun Yat-sen university;The Seventh Affiliated Hospital, Sun Yat-sen university

cyofficial@126.com;cyofficial@126.com;cyofficial@126.com;cyofficial@126.com;cyofficial@126.com+86 13554729650;+86 13554729650;+86 13554729650;+86 13554729650;+86 13554729650

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026